Medical Imaging News

February 14, 2007

Advanced Medical Isotopes Corp Licenses Patent for Actinium-225

Advanced Medical Isotopes Corp (ADMD) has announced the licensing of US Patent 6,680,993 for the methods and processes directed to the preparation of Actinium-225 and daughters having high radiochemical and radionuclidic purity, which may be used for the preparation of radiopharmaceuticals for linkage to such therapeutics as those containing monoclonal antibodies, proteins, peptides, antisense, statin, natural products, and hormones. The alpha-emitting radionuclide Actinium-225 and daughters can be used for both therapeutic and diagnostic purposes.

Alpha-emitting radionuclides, combined with monoclonal antibodies, target specific cancer cells, traveling throughout the bloodstream until they move into and/or lock onto the targeted cells. The high-energy alpha particles do not significantly damage healthy surrounding tissue, resulting in very low side effects.

Studies conducted at the Memorial Sloan-Kettering Cancer Center indicate positive results with acute myeloid leukemia, breast, ovarian, lymphoma, neuroblastoma, and prostrate cancers, according to ADMD.

Read more Medical Imaging News from our archives